Skip to main content

Table 2 Effectiveness for acute pancreatitis with protease inhibitors

From: Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis

Outcomes No. of studies Pooled risk difference NNT Heterogeneity Statistical method by effect model Quality of a body of evidence
Value 95%CI Value 95%CI I2value(%)
Lower Upper NNTB NNTH
Death 17 -0.02 -0.05 0.01 74.8   NNTH 62.4 to ∞ to NNTB 23.4 0 M-H low
High quality studies 6 -0.02 -0.06 0.02   624.6 NNTH 24.6 to ∞ to NNTB 26.7 34.1 M-H
Aprotinin 11 -0.01 -0.05 0.02 89.3   NNTH 38.8 to ∞ to NNTB 20.8 0 M-H
Gabexate mesilate 6 -0.02 -0.07 0.03 54.3   NNTH 33.3 to ∞ to NNTB 14.9 31.1 M-H
Daily dosage >900 mg of GM 5 -0.02 -0.09 0.04 55.2   NNTH 8.3 to ∞ to NNTB 14.C 47.0 M-H
Daily dosage >1500 mg of GM 2 -0.09 -0.33 0.15 33.6   NNTH 17.8 to ∞ to NNTB 8.6 79.0 D-L
Mild pancreatitis 7 0.00 -0.03 0.04   177.5 NNTH 24.5 to ∞ to NNTB 33.9 0 M-H
Moderate to severe pancreatitis 10 -0.03 -0.07 0.01   1604 NNTH 23.0 to ∞ to NNTB 23.7 19.7 M-H
Severe pancreatitis 2 -0.19 -031 -0.08 5.2   3.2 to 12.7 0 M-H
With sponsor 9 -0.02 -0.06 0.02 67.0   NNTH 43.0 to ∞ to NNTB 18.8 15.0 M-H
Without sponsor 8 -0.02 -0.06 0.03 68.4   NNTH 31.9 to ∞ to NNTB 16.5 0 M-H
Abdominal pain 2 -0.26 -0.40 -0.13 3.9 2.5 to 9.6 85.0 D-L   very low
High quality study 1 -0.14 -0.32 0.03 6.9   NNTH 30.1 to ∞ to NNTB 3.1 Uncalculatable M-H
Pseudocyst formation 5 -0.00 -0.05 0.03 298.6   NNTH 27.3 to ∞ to NNTB 23.1 0 M-H low
Intra-abdominal abscess formation 4 -0.01 -0.04 0.02 113.2   NNTH 65.3 to ∞ to NNTB 30.3 0 M-H low
Surgical intervention 3 -0.08 -0.17 -0.00 11.8   6.0 to 443.8 60.5 D0L very low
High quality study 1 0.00 -0.10 0.11   225.8 NNTH 8.9 to ∞ to NNTB 9.7 Uncalculatable M-H
Bowel obstruction 3 -0.06 -0.12 -0.00 6.3   4.0 to 14.5 58.8 D-L very low
High quality study 1 -0.03 -0.08 0.02 33.9   NNTH 44.2 to ∞ to NNTB 12.3 Uncalculatable M-H
Any major complications 5 -0.01 -0.08 0.06 76.4   NNTH 15.7 to ∞ to NNTB 11.1 0 M-H low
  1. NNT number needed to treat; NNTB number needed to treat benefit; NNTH number needed to treat harm; CI confidence intervals; M-H mantel-haenszel; D-L dersimonian-laird; GM, gabexate mesilate.